EUVIMEDEUVIMED entdecken
Crossref

BIX-01294, a pharmacological inhibitor of EHMT2, suppresses retinoblastoma tumorigenesis through MAPK pathway inhibition

Yijia Chen, Jingchao Liu, Tingting Chen, Yanyan Zhang, Chunyue Yao, Shuyi Chen, Guofu Huang

European Journal of Pharmacology · 2026-06 · 1026 · 178953

DOI: 10.1016/j.ejphar.2026.178953 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026-06. Verfasst von Yijia Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and …. Hauptthemen laut MEDLINE: Retinoblastoma, Histone-Lysine N-Methyltransferase, Azepines, Quinazolines. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated the antitumor effects of BIX01294, a pharmacological inhibitor of euchromatic histone-lysine N-methyltransferase 2 (EHMT2), in retinoblastoma and explored the underlying mechanisms. EHMT2 expression was evaluated using Gene Expression Profiling Interactive Analysis (GEPIA), human retinoblastoma specimens, publicly available Gene Expression Omnibus (GEO) datasets, and cultured cell lines. Cell proliferation was assessed using Cell Counting Kit-8 (CCK-8) and 5-ethynyl-2'-deoxyuridine (EdU) incorporation assays. Cell cycle distribution and apoptosis were analysed by flow cytometry. RNA sequencing (RNA-seq), quantitative real-time polymerase chain reaction (qRT-PCR), and western blotting were performed to investigate downstream molecular changes. An orthotopic xenograft model was established to assess the in vivo pharmacological effects of BIX01294. EHMT2 was upregulated in retinoblastoma tissues and in retinoblastoma cell lines. BIX01294 reduced EHMT2 expression, inhibited proliferation, induced apoptosis, and caused cell cycle arrest, accompanied by downregulation of cyclin A, cyclin-dependent kinase 2 (CDK2), cyclin B, and phosphorylated cell division cycle 2 (p-CDC2). Under the same 48 h treatment conditions, ARPE-19 cells showed minimal changes in viability and no obvious alterations in apoptosis or cell-cycle distribution, supporting a degree of pharmacological selectivity. Transcriptomic profiling and protein analysis indicated that BIX01294 treatment was associated with attenuation of mitogen-activated protein kinase (MAPK) signalling. In the orthotopic xenograft model, BIX01294 reduced tumour burden and Ki-67 staining. These findings support EHMT2 as a potential pharmacological target in retinoblastoma; however, additional mechanistic studies are required to define the causal link between EHMT2 inhibition and MAPK pathway modulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinoblastomaHistone-Lysine N-MethyltransferaseAzepinesQuinazolinesMAP Kinase Signaling SystemCarcinogenesisAntineoplastic AgentsHumansAnimalsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticMiceXenograft Model Antitumor AssaysHistocompatibility AntigensMice, Nude

Stichwörter der Autor:innen

ApoptosisBIX01294Cell cycleEHMT2MAPK signallingRetinoblastoma

Substanzen

Histone-Lysine N-MethyltransferaseBIX 01294AzepinesQuinazolinesEHMT2 protein, humanHistocompatibility AntigensAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, 510060, People's Republic of China.
  • Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Department of Ophthalmology, Jiangxi Provincial People's Hospital & the First Affiliated Hospital of Nanchang Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, 510060, People's Republic of China. Electro…

Förderung

  • Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology

Zitieren

APA

Chen, Y., Liu, J., Chen, T., Zhang, Y., Yao, C., Chen, S., & Huang, G. (2026). BIX-01294, a pharmacological inhibitor of EHMT2, suppresses retinoblastoma tumorigenesis through MAPK pathway inhibition. European Journal of Pharmacology, 1026, 178953. https://doi.org/10.1016/j.ejphar.2026.178953

Vancouver

Chen Y, Liu J, Chen T, Zhang Y, Yao C, Chen S, et al. BIX-01294, a pharmacological inhibitor of EHMT2, suppresses retinoblastoma tumorigenesis through MAPK pathway inhibition. European Journal of Pharmacology. 2026;1026:178953. doi:10.1016/j.ejphar.2026.178953

BibTeX
@article{Chen2026,
  author = {Chen, Yijia and Liu, Jingchao and Chen, Tingting and Zhang, Yanyan and Yao, Chunyue and Chen, Shuyi and Huang, Guofu},
  title = {BIX-01294, a pharmacological inhibitor of EHMT2, suppresses retinoblastoma tumorigenesis through MAPK pathway inhibition},
  journal = {European Journal of Pharmacology},
  year = {2026},
  volume = {1026},
  pages = {178953},
  doi = {10.1016/j.ejphar.2026.178953}
}
Kostenlos starten →